LB PHARMACEUTICALS INC (LBRX)

Pharmaceutical Preparations · market cap $1.3B · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

LB Pharmaceuticals Inc (LBRX) is a clinical-stage pharmaceutical company with 16 employees and a ~$901M market cap built almost entirely on a single asset: LB-102, a Phase 2 CNS compound for schizophrenia with an undisclosed mechanism of action. The company holds $320.7M in cash, giving it roughly 41 months of runway, and carries no debt, making it effectively a well-capitalized binary bet on Phase 2 readout.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10
2027-06-30Phase 3imp 7/10

Pipeline

Asset	Phase	Indication
LB-102	Phase 2	Schizophrenia

Price & technical context

3-month

+11.5%

6-month

+50.3%

12-month

+136.1%

52-wk range

$14.61–$49.48

vs 50-day MA

-14.9%

vs 200-day MA

+21.0%

Realized vol

61.8%

Max drawdown

-24.7%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LBRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.